Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses
- 14 March 2022
- journal article
- letter
- Published by Elsevier in Kidney International
- Vol. 101 (6) , 1287-1289
Abstract
No abstract availableFunding Information
- Forschungszentrum Jülich
- Stiftung Mercator
This publication has 5 references indexed in Scilit:
- A Vector-Based Vaccine Dose After 3 Doses of mRNA-Based COVID-19 Vaccination Does Not Substantially Improve Humoral SARS-CoV-2 Immunity in Renal Transplant RecipientsKidney International Reports, 2022
- Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2022
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variantCell, 2022
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ TransplantJAMA Network Open, 2021